Monotherapy in patients with type 2 diabetes mellitus

被引:5
作者
Rhee, Sang Youl [1 ]
Kim, Hyun Jin [2 ]
Ko, Seung-Hyun [3 ]
Hur, Kyu Yeon [4 ]
Kim, Nan-Hee [5 ]
Moon, Min Kyong [6 ]
Park, Seok-O [7 ]
Lee, Byung-Wan [8 ]
Choi, Kyung Mook [5 ]
Kim, Jin Hwa [9 ]
机构
[1] Kyung Hee Univ, Sch Med, Dept Endocrinol & Metab, Seoul, South Korea
[2] Chungnam Natl Univ, Sch Med, Dept Internal Med, Div Endocrinol & Metab, Daejeon, South Korea
[3] Catholic Univ Korea, Coll Med, Dept Internal Med, Div Endocrinol & Metab, Seoul, South Korea
[4] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Endocrinol & Metab,Dept Internal Med, Seoul, South Korea
[5] Korea Univ, Coll Med, Dept Internal Med, Div Endocrinol & Metab, Seoul, South Korea
[6] Seoul Natl Univ, Seoul Metropolitan Govt, Boramae Med Ctr, Div Endocrinol & Metab,Dept Internal Med, Seoul, South Korea
[7] Gwangmyeong Sungae Hosp, Dept Internal Med, Gwangmyeong, South Korea
[8] Yonsei Univ, Coll Med, Dept Internal Med, Div Endocrinol & Metab, Seoul, South Korea
[9] Chosun Univ, Coll Med, Dept Internal Med, Div Endocrinol & Metab, Gwangju, South Korea
关键词
Diabetes mellitus; type; 2; Hypoglycemic agents; Metformin; Practice guideline; DIPEPTIDYL PEPTIDASE-4 INHIBITORS; GLUCOSE-LOWERING EFFICACY; LONG-TERM METFORMIN; CARDIOVASCULAR OUTCOMES; PREVENTION PROGRAM; GLYCEMIC CONTROL; BLOOD-GLUCOSE; LIFE-STYLE; METAANALYSIS; EVENTS;
D O I
10.3904/kjim.2017.312
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In order to improve the quality of life and to prevent chronic complications related to diabetes mellitus, intensive lifestyle modification and proper medication are needed from the early stage of diagnosis of type 2 diabetes mellitus (T2DM). When using the first medication for diabetic patients, the appropriate treatment should be selected considering the clinical characteristics of the patient, efficacy of the drug, side effects, and cost. In general, the use of metformin as the first treatment for oral hypoglycemic monotherapy is recommended because of its excellent blood glu-cose-lowering effect, relatively low side effects, long-term proven safety, low risk of hypoglycemia, and low weight gain. If metformin is difficult to use as a first-line treatment, other appropriate medications should be selected in view of the clinical situation. If the goal of achieving glycemic control is not achieved by monotherapy, a combination therapy with different mechanisms of action should be initiated promptly.
引用
收藏
页码:959 / 966
页数:8
相关论文
共 54 条
  • [51] Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes
    Wing, Rena
    Bolin, Paula
    Brancati, Frederick L.
    Bray, George A.
    Clark, Jeanne M.
    Coday, Mace
    Crow, Richard S.
    Curtis, Jeffrey M.
    Egan, Caitlin M.
    Espeland, Mark A.
    Evans, Mary
    Foreyt, John P.
    Ghazarian, Siran
    Gregg, Edward W.
    Harrison, Barbara
    Hazuda, Helen P.
    Hill, James O.
    Horton, Edward S.
    Hubbard, Van S.
    Jakicic, John M.
    Jeffery, Robert W.
    Johnson, Karen C.
    Kahn, Steven E.
    Kitabchi, Abbas E.
    Knowler, William C.
    Lewis, Cora E.
    Maschak-Carey, Barbara J.
    Montez, Maria G.
    Murillo, Anne
    Nathan, David M.
    Patricio, Jennifer
    Peters, Anne
    Pi-Sunyer, Xavier
    Pownall, Henry
    Reboussin, David
    Regensteiner, Judith G.
    Rickman, Amy D.
    Ryan, Donna H.
    Safford, Monika
    Wadden, Thomas A.
    Wagenknecht, Lynne E.
    West, Delia S.
    Williamson, David F.
    Yanovski, Susan Z.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (02) : 145 - 154
  • [52] Comparison of the Efficacy of Glimepiride, Metformin, and Rosiglitazone Monotherapy in Korean Drug-Naive Type 2 Diabetic Patients: The Practical Evidence of Antidiabetic Monotherapy Study
    Yoon, Kun Ho
    Shin, Jeong Ah
    Kwon, Hyuk Sang
    Lee, Seung Hwan
    Min, Kyung Wan
    Ahn, Yu Bae
    Yoo, Soon Jib
    Ahn, Kyu Jeung
    Park, Sung Woo
    Lee, Kwan Woo
    Sung, Yeon Ah
    Park, Tae Sun
    Kim, Min Seon
    Kim, Yong Ki
    Nam, Moon Suk
    Kim, Hye Soon
    Park, Ie Byung
    Park, Jong Suk
    Woo, Jeong Taek
    Son, Ho Young
    [J]. DIABETES & METABOLISM JOURNAL, 2011, 35 (01) : 26 - 33
  • [53] Yun JS, 2016, DIABETES METAB J, V40, P423
  • [54] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
    Zinman, Bernard
    Wanner, Christoph
    Lachin, John M.
    Fitchett, David
    Bluhmki, Erich
    Hantel, Stefan
    Mattheus, Michaela
    Devins, Theresa
    Johansen, Odd Erik
    Woerle, Hans J.
    Broedl, Uli C.
    Inzucchi, Silvio E.
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (22) : 2117 - 2128